Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of “Moderate Buy” by Analysts

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given a consensus recommendation of “Moderate Buy” by the six research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several equities research analysts have commented on IRWD shares. Craig Hallum lowered their price target on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday. StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th.

Ironwood Pharmaceuticals Stock Down 1.6 %

Shares of NASDAQ:IRWD opened at $3.71 on Friday. The business has a 50-day moving average price of $3.90 and a 200-day moving average price of $4.56. The stock has a market cap of $593.70 million, a price-to-earnings ratio of -123.67 and a beta of 0.34. Ironwood Pharmaceuticals has a 52-week low of $3.06 and a 52-week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.07). The business had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business’s revenue was down 19.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.12 earnings per share. As a group, equities analysts anticipate that Ironwood Pharmaceuticals will post 0.08 EPS for the current fiscal year.

Insider Buying and Selling at Ironwood Pharmaceuticals

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now directly owns 309,572 shares in the company, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. Journey Strategic Wealth LLC acquired a new position in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $45,000. China Universal Asset Management Co. Ltd. increased its holdings in Ironwood Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 3,209 shares in the last quarter. EMC Capital Management raised its position in Ironwood Pharmaceuticals by 693.0% during the fourth quarter. EMC Capital Management now owns 23,893 shares of the biotechnology company’s stock worth $106,000 after acquiring an additional 20,880 shares during the period. Pacer Advisors Inc. lifted its holdings in Ironwood Pharmaceuticals by 4.0% during the fourth quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company’s stock valued at $51,967,000 after purchasing an additional 450,949 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $53,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.